



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Comwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbalas  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffie  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcam  
Robert C. Millonig  
Lawrence B. Bugalsky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Jeffrey T. Helvey\*  
Heidi L. Kraus  
Crystal D. Sayles  
Edward W. Yee  
Albert L. Ferro\*  
Donald R. Banowitz  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver,  
Kendrick P. Patterson  
Vincent L. Capuano  
Albert J. Fasulo II\*  
Eldora Ellison Floyd  
W. Russell Swindell

Thomas C. Fiala  
Brian J. Del Buono\*  
Virgil Lee Beaston\*  
Reginald D. Lucas\*  
Kimberly N. Reddick  
Theodore A. Wood  
Elizabeth J. Haanes  
Bruce E. Chalker  
Joseph S. Ostroff  
Frank R. Cottingham\*  
Christine M. Uhller  
Rae Lynn Prengaman\*  
Jane Shershonovich\*  
Lawrence J. Carroll\*

Senior Counsel  
Samuel L. Fox  
Kenneth C. Bass III

Registered Patent Agents  
Karen R. Markowicz  
Andrea J. Kamache  
Nancy J. Leith  
Joseph M. Conrad III  
Ann E. Summerfield  
Helene C. Carlson  
Gaby L. Longsworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Angelique G. Uy  
Boris A. Matvenko  
Mary B. Tung

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Admitted only in Texas

February 28, 2002

WRITER'S DIRECT NUMBER:

(202) 371-2619

INTERNET ADDRESS:

SCHWARTZ@SKGF.COM

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. National Phase of PCT/GB99/01388  
International Filing Date: May 5, 1999  
U.S. Appl. No. 09/674,733  
For: **Melanocortin 1 Receptor Selective Compounds**  
Inventors: Szardenings *et al.*  
Our Ref: 1085.0050000/RWE/ALS

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Status Inquiry Letter; and
2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Aaron L. Schwartz  
Agent for Applicants  
Registration No. 48,181

RWE/ALS/lam  
Enclosures

Sterne, Kessler, Goldstein & Fox PLLC : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : [www.skgf.com](http://www.skgf.com)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Szardenings *et al.*

Appl. No. 09/674,733  
(U.S. Natl. Phase of PCT/GB99/01388)

Int'l Filing Date: May 5, 1999

For: **Melanocortin 1 Receptor  
Selective Compounds**

Art Unit: *To be assigned*

Examiner: *To be assigned*

Atty. Docket: 1085.0050000/RWE/ALS

**Status Inquiry Letter**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Please advise the undersigned of the present status of the above-identified patent application.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Aaron L. Schwartz".

Aaron L. Schwartz  
Agent for Applicants  
Registration No. 48,181

Date: 2/28/02

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600